MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that the U.S. District Court of Delaware issued its ruling on post-trial motions filed by the parties in Edwards Lifesciences v. CoreValve, Inc. In its ruling, the Court denied Edwards Lifesciences' request for a permanent injunction to prohibit Medtronic from manufacturing its CoreValve® System in the U.S. As such, Medtronic does not anticipate any interruption to supply of its CoreValve System. The Court also denied Edwards’ request for enhanced damages.
The Court also affirmed the jury's verdict and damages award against Medtronic on patent infringement. Medtronic disagrees with this conclusion and plans to appeal.
The Court's ruling has no impact on the Medtronic CoreValve U.S. Pivotal Trial, which began in December.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.